Merrill stops coverage of NPS Pharmaceuticals

Merrill Lynch analyst Eric Ende is terminating coverage of NPS Pharmaceuticals Inc. with no final rating as the Preos development is effectively halted without a partner. The analyst also cited limited investor interest and a re-allocation of resources as reasons for the termination. Shares of the Salt Lake City-based pharmaceutical company were up 30 cents, or 6.25%, at $5.10 on volume of 716,002 shares versus the three-month running average of 1,042,150 shares. (Nasdaq: NPSP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.